Starting Nov. 4, babies born in 2024 can get Beyfortus — also known as nirsevimab — to protect against severe illness from ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
“This is the first time Alberta has included the RSV vaccine in its publicly funded immunization program for seniors, ...
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr ...
GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...
Health officials are concerned millions of people with health issues aren't taking up vaccination offers as UK faces a triple ...
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...
Important information new parents need to know about Respiratory Syncytial Virus, or RSV. It comes around when the weather ...
The Centers for Disease Control and Prevention is urging some people to get additional doses of the COVID-19 vaccine for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback